Instructor Notes — Chapter 17

Teaching notes

What this chapter is actually for

Chapter 5 gave students the evidence ladder. Chapter 17 is where they find out that using it correctly is socially difficult.

The chapter is not a debunking, and if that is how you frame it in the room, it will fail in a specific and predictable way. Some proportion of any group studying this material has used or is using this compound. That proportion is higher than you think and it will not identify itself, particularly if the first five minutes of the session establish that doing so invites ridicule. Once that signal has been sent, those students stop participating, and they are the students the chapter was written for.

The intellectual task is stated in §17.1 and it is the only thing that needs to survive the session: a substantial, competently conducted, multi-model animal literature and a completely unanswered human question are not in contradiction. Explaining why they are not is the work. A student who leaves able to say "there's no evidence for BPC-157" has learned nothing transferable and is, strictly, wrong.

The two failure modes, and they are symmetrical

Failure mode one — the room decides the science is fake. Watch for this in the first twenty minutes. It is comfortable, it flatters everyone present, and it is false. The correction is §17.3 and §17.4: make students state the case for the compound before anyone is allowed to criticize it. If they cannot do it well, they are not ready to evaluate it. Consider running §17.3 as a straight presentation with criticism explicitly forbidden until it is finished.

Failure mode two — the room decides the ❌ is unfair. This usually arrives via the funding argument, and it arrives late, often from your strongest student. It is a genuinely good objection and §17.10 steelmans it deliberately. The answer is not to dismiss it but to follow it: if the absence of funding upgraded a rating, every unfunded compound would be upgraded — including the great majority that do not work. Let the student arrive there themselves; it lands much harder.

Both failures are the same error — substituting a story about the world for a report on the evidence — and it is worth naming that out loud once both have appeared.

Sequencing that works

1. §17.3 and §17.4 first, uncritically. Present the animal literature at full strength. Do not telegraph the ❌.
2. Case Study 1 next. One study, read all the way down. Students who have just been told the literature is good will discover for themselves how precisely each study's conclusion has to be worded. The sentence ladder is the highest-yield ten minutes in the chapter — run it on the board and make the room vote on where the sentence stops being true. The votes will spread across steps ② through ④, which is the lesson.
3. §17.5 only after they have felt the pull of the animal data.
4. §17.6's ten-minute check, performed live. Genuinely open PubMed and ClinicalTrials.gov in the room and do it together, on the screen. This is the single most valuable thing you can do with the session. Then repeat with semaglutide as a calibration — the contrast, performed back-to-back, does more work than any lecture on the ladder.
5. §17.10 and §17.11 to close. Never close on §17.9; ending on safety leaves the room in the menace register.

Specific things students get wrong

They think ❌ means "doesn't work." Every cohort. The rating box's fifth line exists for this and it is worth reading aloud verbatim. Test it: ask what would have to be true for a compound to deserve a rating meaning "shown not to work," and let them discover the system does not have one. That is a real limitation of a four-tier scheme and worth admitting.

They think more studies would help. Ask directly: which of §17.5's four problems is fixed by a larger, better-controlled animal study? The answer is none, and watching a room work that out is the chapter in miniature.

They conflate stability with bioavailability. This is not a subtle error and it is nearly universal, because nobody has ever given them the distinction. One sentence fixes it permanently: stability asks "does it survive?"; bioavailability asks "does it arrive?" Use it early; §17.8 then takes ten minutes instead of thirty.

They accept "no reported harm" as a safety finding. Ask them to describe the path by which a serious adverse event in a gray-market user becomes a "report." They will fail to complete the chain, which is the point.

They over-read the neovascularization worry in §17.7. The text hedges it heavily and deliberately. If a student states it as a warning, correct it — the chapter's whole posture collapses if it starts manufacturing risks to balance the ledger.

Handling disclosure in the room

Someone may disclose use, publicly or privately. The chapter is written on the assumption that this will happen.

Do not congratulate and do not correct. The useful response is procedural: what would change your mind? — the same question the chapter asks of itself in §17.11. If they have an answer, they are doing exactly what the book teaches. If they do not, that is the conversation, and it is the same conversation you would have with a student who was certain the compound was worthless.

A private disclosure is not an invitation to advise. Point to §17.9's one actionable sentence (tell your clinician) and to Chapter 39, and stop there.

Assessment notes

• Exercise 17.36 is the chapter's real assessment and it is not gradeable on the conclusion, only on execution. See answers/ch17.md for what to look for; move 1 and move 6 are the diagnostics.
• Exercise section F items are the fastest way to see whether a student has internalized "concede what is true first." A response that opens by attacking the claim has missed the point regardless of its accuracy.
• Quiz Q22 (the funding argument) and Q24 (conference abstract) discriminate best. Q16 is a gimme that is nonetheless worth including because a surprising number get it wrong.

Time

A single session covers §17.1–§17.6 plus the live database check. Two sessions is better: split at §17.7, giving the second session tendon pathology, the oral claim, safety, and the two closing sections. Case Study 2 works well as pre-reading for session two, since it belongs to Chapter 6's material and students can handle it unaided.